Oncotarget

Research Papers:

Dot1l expression predicts adverse postoperative prognosis of patients with clear-cell renal cell carcinoma

Yang Qu, Li Liu, Jiajun Wang, Wei Xi, Yu Xia, Qi Bai, Ying Xiong, Qilai Long, Jiejie Xu _ and Jianming Guo

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:84775-84784. https://doi.org/10.18632/oncotarget.12476

Metrics: PDF 1309 views  |   HTML 1516 views  |   ?  


Abstract

Yang Qu1,*, Li Liu1,*, Jiajun Wang1,*, Wei Xi1, Yu Xia1, Qi Bai1, Ying Xiong1, Qilai Long1, Jiejie Xu2, Jianming Guo1

1Department of Urology, Zhongshan Hospital, Fudan University, Shanghai 200032, China

2Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China

*These authors have contributed equally to this work

Correspondence to:

Jiejie Xu, email: jjxufdu@fudan.edu.cn

Jianming Guo, email: guo.jianming@zs-hospital.sh.cn

Keywords: clear-cell renal cell carcinoma, Dot1l, overall survival, prognostic biomarker, nomogram

Received: August 15, 2016    Accepted: September 22, 2016    Published: October 5, 2016

ABSTRACT

Background: Disruptor of telomeric silencing 1-like (Dot1l), a histone methyltransferase that targets the histone H3 lysine 79 (H3K79), has been reported that its high expression is associated with various cancers, while the association between Dot1l expression and clear-cell renal cell carcinoma (ccRCC) is still unknown.

Patients and Methods: We retrospectively enrolled 282 patients with ccRCC undergoing nephrectomy from a single institution between 2005 and 2007, with a median follow-up of 99 months. Dot1l expression was evaluated by immunohistochemistry in clinical specimens. We compared the clinical outcomes by Kaplan-Meier survival analyses and assessed the prognostic value of Dot1l expression. Harrell’s concordance index (C-index) was used to assess the predictive accuracy of different prognostic models.

Results: Higher Dot1l expression indicated poorer OS (P<0.001) and RFS (P<0.001) in patients with ccRCC. Moreover, Dot1l expression could stratify ccRCC patients in pT stage, Fuhrman grade and SSIGN/ Leibovich subgroups, which might redefine individual risk stratification. Multivariate analyses further indicated that Dot1l expression was an independent prognostic factor for OS (P=0.007) and RFS (P=0.001). The prognostic accuracy of conventional prognostic models was notably improved with Dot1l integration. Two nomograms and calibration plots were built to predict OS and RFS for patients with ccRCC and performed better based on C-index value.

Conclusion: Dot1l expression is a promising independent prognostic indicator for postoperative recurrence and survival of patients with ccRCC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 12476